De novo malignancy after lung transplantation in Japan

Miyazaki, Takuro; Oto, Takahiro; Okumura, Meinoshin; Date, Hiroshi; Shiraishi, Takeshi; Okada, Yoshinori; Chida, Masayuki; Kondo, Takashi; Nagayasu, Takeshi

doi:10.1007/s11748-016-0672-x

Cited by 14 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are few articles related to lung transplantation, and only one of which meets our screening conditions was selected whose title is "De Novo Malignancy after Lung Transplantation in Japan" [28]. It summarizes 179 lung transplantation operations performed in 7 institutions in Japan from 2001 to 2010, of which 18 recipients (10.1%) developed new malignancies.…”

Section: Morbidity Of Carcinoma Of Postheart Transplantationmentioning

confidence: 99%

[Retracted] Current Status of Malignant Tumors after Organ Transplantation

Shen

Cen

Tan

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. To analyze the diagnosis and treatment of patients with concomitant malignant tumors after organ transplantation by compiling data from organ transplantation patients. Methods. By searching CNKI and PubMed databases, we made a systematic analysis of the studies of postorgan transplantation complicating malignant tumors in the last decade. Results. There were 10 articles on malignant tumors after renal transplantation, 8 articles on liver transplantation, 2 articles on heart transplantation, and 1 article on lung transplantation. The incidence of malignant tumors complicating renal transplantation is 10.4% in Europe, with skin cancer and Kaposi’s sarcoma being common; the incidence in the United States is 3.4%, with PTLD having the highest incidence; the incidence of malignant tumors is relatively lowest in Asia, with gastrointestinal malignancies being the main ones. The mean time to complication of malignancy after renal transplantation is 3.83 years. The incidence of concurrent malignancies after liver transplantation is 8.8% in Europe, where skin cancer and Kaposi’s sarcoma are common; 5.6% in Asia, where gastrointestinal tract tumors are prevalent; and 4.5% in the United States, where gastrointestinal tract tumors, PTLD, and hematologic diseases are predominant. The mean time to complication of malignancy after liver transplantation is 4.79 years. The incidence of malignancy after heart transplantation is 6.8-10.7%. The incidence of malignancy after lung transplantation is about 10.1%. Minimization of immunosuppression or modification of immunosuppression regimens may be a key component of cancer prevention. mTOR inhibitors and phenolate (MMF) reduce the incidence of de novo malignancies in patients after solid organ transplantation. Surgical treatment improves survival in patients with early malignancies. The use of external beam radiation therapy in the treatment of hepatocellular carcinoma is limited due to the risk of radiation liver disease. Conclusions. The risk of concomitant malignancy needs to be guarded for 5 years of immunosuppressive therapy after organ transplantation surgery. Adjusting the immunosuppressive treatment regimen is an effective way to reduce concurrent malignancies. Systemic chemotherapy or radiotherapy requires vigilance against the toxic effects of drug metabolism kinetics on the transplanted organ.

show abstract

Section: Morbidity Of Carcinoma Of Postheart Transplantationmentioning

confidence: 99%

[Retracted] Current Status of Malignant Tumors after Organ Transplantation

Shen

Cen

Tan

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Although two recent Japanese studies revealed that de novo malignancy occured at an incidence of 10.1% and post transplant lymphoproliferative disorder was the most common malignancy after lung transplantation, regardless the source of organ was from living donor or cadaver [18, 19], the cancer risk among Asian organ transplant recipients has been limited. However, Taiwan launched the National Health Insurance (NHI) Program in 1995, with nationwide coverage.…”

Section: Introductionmentioning

confidence: 99%

De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study

et al. 2016

View full text Add to dashboard Cite

Organ transplant recipients appear to have a higher risk of de novo malignancy. The aim of the study was designed to estimate cancer risk in heart, lung, kidney and liver transplant recipients. The cohort study used the Taiwan National Health Insurance Research Database (1996-2011) and followed the outcomes of organ recipients until 2012. De novo cancer and mortality rates after organ transplantation were evaluated using standardized incidence ratios, excess absolute risks of cancer, and standardized mortality ratios in recipients were compared with those in the general population. We identified 40, 231, 2, and 115 patients who developed cancer after heart, kidney, lung, and liver transplantation, which corresponded to a cancer incidence of 878.4, 1101.2, 728.9, and 1361.4 cases per 100,000 person-years, respectively. In heart, kidney, lung, and liver recipients, the overall standardized incidence ratios were 1.65 (1.21-2.24), 3.33 (2.93-3.79), 1.82 (0.45-7.27) and 3.37 (2.81-4.05) and the overall standardized mortality ratios were 5.45 (4.96-5.98), 1.47 (1.34-1.61), 8.92 (7.10-11.20), and 3.83 (3.48-4.20), respectively. These results reveal a three-fold increase in de novo cancer risk in organ transplant patients compared with the general population. This study illustrated the importance of de novo malignancy after organ transplantation.

show abstract

“…We report an incidence of 7.6% similar to others studies (5.2% to 17%). 10 However, this incidence may even be underestimated, as the study included all LT patients with a very short post-LT follow-up. As described by ISHLT, the most common malignancies in this series were skin cancer and PTLD.…”

Section: Discussionmentioning

confidence: 99%

Malignancies following lung transplantation: the Portuguese experience

Caldeira¹,

Silva²,

Caires³

et al. 2019

JCPCR

View full text Add to dashboard Cite

Malignancy is an important complication after lung transplantation (LT), which is related to common risk factors in these patients, oncogenic viruses and immunosuppression therapy (IST). We retrospectively analyzed all cases of malignancy in the 182 patients that underwent LT between June 2001 and December 2017 in Portugal. We noticed an incidence of 7.6%, similar to that described in the literature, with a mean age of 53 years and a mean time after LT of 25 months. As in other series, the most common types of cancer were skin cancer (2.7%), post transplant lymphoproliferative disorders (2.2%) and lung cancer (1.6%). Unexpectedly we found an important incidence of gastric cancer (1,1%) not previously described in the literature that we relate to the elevated incidence of this cancer in our country. All patients underwent treatment and IST adjustments, according to a multidisciplinary team approach. In this series, 4 patients died due to cancer (33.3%) with a median survival of 26 months. We conclude that cancer is an important complication after LT and further investigation and awareness is needed to optimize diagnosis and management of this condition.

show abstract

De novo malignancy after lung transplantation in Japan

Abstract: This is the first national survey of the incidence of de novo malignancy after lung transplantation in Japan. The incidence was 10.1 % and post-transplant lymphoproliferative disorder was the most common malignancy.

Cited by 14 publications

References 21 publications

[Retracted] Current Status of Malignant Tumors after Organ Transplantation

[Retracted] Current Status of Malignant Tumors after Organ Transplantation

De novo malignancy in organ transplant recipients in Taiwan: a nationwide cohort population study

Malignancies following lung transplantation: the Portuguese experience

Contact Info

Product

Resources

About